Reviews in Endocrine and Metabolic Disorders

, Volume 17, Issue 3, pp 381–388 | Cite as

Hereditary syndromes predisposing to endocrine tumors and their skin manifestations

Article
First Online:

Abstract

We often think of the lentiginoses, phacomatoses and other neurocutaneous syndromes as conditions that affect the skin and also predispose to a variety of tumors. However, we rarely think of Peutz-Jeghers syndrome (PJS), Carney complex (CNC), Cowden disease (CD), neurofibromatosis type-1 (NF-1) or tuberous sclerosis (TSC) as conditions that are multiple endocrine neoplasias (MEN). Indeed, all of these conditions predispose to a variety of endocrine tumors, in addition to many other neoplasms. On the other hand, the classic MENs, type 1 and 2 (MEN-1 and MEN-2, respectively) are almost never thought in terms of their skin manifestations. In this review, we present extensively the MEN-1, MEN-2 and PJS syndromes, and briefly refer to CD, NF-1, and TSC. CNC is discussed in another article in this journal issue.

Keywords

Multiple endocrine neoplasia Hereditary tumor syndrome Peutz-Jeghers syndrome Cowden disease Neurofibromatosis type 1 Tuberous sclerosis 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

This review was supported by the research project Z01-HD008920 (Principal Investigator: Dr. Constantine A Stratakis) of the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA.

Compliance with ethical standards

Conflict of interest

The author declares that he has no conflict of interest.

References

  1. 1.
    Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Marx SJ, Agarwal SK, Kester MB, et al. Multiple endocrine neoplasia type 1: Clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog. Horm. Res. 1999;54:397–438. discussion 438-399.Google Scholar
  3. 3.
    Vasen HF, Lamers CB, Lips CJ. Screening for the multiple endocrine neoplasia syndrome type I. A study of 11 kindreds in the Netherlands. Arch. Intern. Med. 1989;149(12):2717–22.CrossRefPubMedGoogle Scholar
  4. 4.
    Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: Clinical and genetic topics. Ann. Intern. Med. 1998;129(6):484–94.CrossRefPubMedGoogle Scholar
  5. 5.
    Stratakis CA, Schussheim DH, Freedman SM, et al. Pituitary macroadenoma in a 5-year-old: An early expression of multiple endocrine neoplasia type 1. The journal of clinical endocrinology and metabolism. J. Clin. Endocrinol. Metab. 2000;85(12):4776–80.PubMedGoogle Scholar
  6. 6.
    Vashi N, Hunt R, Fischer M, Meehan S, Pomeranz MK. Angiofibromas in multiple endocrine neoplasia type 1. Dermatol Online J. 2012;18(12):20.PubMedGoogle Scholar
  7. 7.
    Saggini A, Brandi ML. Skin lesions in hereditary endocrine tumor syndromes. Endocr. Pract. 2011;17(Suppl 3):47–57.CrossRefPubMedGoogle Scholar
  8. 8.
    Asgharian B, Turner ML, Gibril F, Entsuah LK, Serrano J, Jensen RT. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: Prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J. Clin. Endocrinol. Metab. 2004;89(11):5328–36.CrossRefPubMedGoogle Scholar
  9. 9.
    Sakurai A, Matsumoto K, Ikeo Y, Nishio SI, Kakizawa T, Arakura F, Ishihara Y, Saida T, Hashizume K. Frequency of facial angiofibromas in Japanese patients with multiple endocrine neoplasia type 1. Endocr. J. 2000;47(5):569–73.CrossRefPubMedGoogle Scholar
  10. 10.
    Darling TN, Skarulis MC, Steinberg SM, Marx SJ, Spiegel AM, Turner M. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch. Dermatol. 1997;133(7):853–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Pack S, Turner ML, Zhuang Z, Vortmeyer AO, Böni R, Skarulis M, Marx SJ, Darling TN. Cutaneous tumors in patients with multiple endocrine neoplasia type 1 show allelic deletion of the MEN1 gene. J Invest Dermatol. 1998;110(4):438–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Baldauf C, Vortmeyer AO, Koch CA, Sticherling M. Combination of multiple skin malignancies with multiple endocrine neoplasia type 1: Coincidental or pathogenetically related? Dermatology. 2009;219(4):365–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best Pract. Res. Clin. Endocrinol. Metab. 2010;24(3):355–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Almeida MQ, Stratakis CA. Solid tumors associated with multiple endocrine neoplasias. Cancer Genet. Cytogenet. 2010;203(1):30–6.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Schernthaner-Reiter MH, Trivellin G, Stratakis CA. MEN1, MEN4, and Carney complex: Pathology and molecular genetics. Neuroendocrinology. 2016;103(1):18–31.Google Scholar
  16. 16.
    Gagel RF. Ret protooncogene mutations and endocrine neoplasia--a story intertwined with neural crest differentiation. Endocrinology. 1996;137(5):1509–11.PubMedGoogle Scholar
  17. 17.
    Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Edery P, Eng C, Munnich A, Lyonnet S. RET in human development and oncogenesis. BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology. 1997;19(5):389–95.CrossRefGoogle Scholar
  19. 19.
    Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T, Tschen JA. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann. Intern. Med. 1989;111(10):802–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Borrego S, Eng C, Sanchez B, Saez ME, Navarro E, Antinolo G. Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. J. Clin. Endocrinol. Metab. 1998;83(9):3361–4.Google Scholar
  21. 21.
    Eng C, Mulligan LM. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Hum. Mutat. 1997;9(2):97–109.CrossRefPubMedGoogle Scholar
  22. 22.
    Hoff AO, Cote GJ, Gagel RF. Multiple endocrine neoplasias. Annu. Rev. Physiol. 2000;62:377–411.CrossRefPubMedGoogle Scholar
  23. 23.
    Angrist M, Bolk S, Halushka M, Lapchak PA, Chakravarti A. Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a hirschsprung disease patient. Nat. Genet. 1996;14(3):341–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Decker RA, Peacock ML, Watson P. Hirschsprung disease in MEN 2A: Increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum. Mol. Genet. 1998;7(1):129–34.CrossRefPubMedGoogle Scholar
  25. 25.
    Koch CA. Molecular pathogenesis of MEN2-associated tumors. Familial Cancer. 2005;4(1):3–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Brauer VF, Scholz GH, Neumann S, Lohmann T, Paschke R, Koch CA. RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: Should thyroidectomy be performed ? Endocr. Pract. 2004;10(1):5–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Scapineli JO, Ceolin L, Puñales MK, Dora JM, Maia AL. MEN 2A-related cutaneous lichen amyloidosis: Report of three kindred and systematic literature review of clinical, biochemical and molecular characteristics. Fam cancer. 2016Rodriguez FJ, Stratakis CA, Evans DG. Genetic predisposition to peripheral nerve neoplasia: Diagnostic criteria and pathogenesis of neurofibromatoses, carney complex, and related syndromes. Acta Neuropathol. 2012;123(3):349–67.CrossRefGoogle Scholar
  28. 28.
    Verga U, Fugazzola L, Cambiaghi S, Pritelli C, Alessi E, Cortelazzi D, Gangi E, Beck-Peccoz P. Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin. Endocrinol. 2003;59(2):156–61.CrossRefGoogle Scholar
  29. 29.
    Lodish MB, Stratakis CA. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert. Rev. Anticancer. Ther. 2008;8(4):625–32.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Boikos SA, Stratakis CA. Molecular mechanisms of medullary thyroid carcinoma: Current approaches in diagnosis and treatment. Histol. Histopathol. 2008;23(1):109–16.PubMedGoogle Scholar
  31. 31.
    Lodish M, Dagalakis U, Chen CC, Sinaii N, Whitcomb P, Aikin A, Dombi E, Marcus L, Widemann B, Fox E, Chuk M, Balis F, Wells Jr S, Stratakis CA. (111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents. J. Clin. Endocrinol. Metab. 2012;97(2):E207–12.CrossRefPubMedGoogle Scholar
  32. 32.
    Nella AA, Lodish MB, Fox E, Balis FM, Quezado MM, Whitcomb PO, Derdak J, Kebebew E, Widemann BC, Stratakis CA. Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient. J. Clin. Endocrinol. Metab. 2014;99(9):3055–9.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Lodish MB, Stratakis CA. The differential diagnosis of familial lentiginosis syndromes. Familial Cancer. 2011;10(3):481–90.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Sammour T, Hayes IP, Hill AG, Macrae FA, Winter DC. Familial colorectal cancer syndromes: An overview of clinical management. Expert Rev Gastroenterol Hepatol. 2015;9(6):757–64.PubMedGoogle Scholar
  35. 35.
    Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Friedl W, Møller P, Hes FJ, Järvinen H, Mecklin JP, Nagengast FM, Parc Y, Phillips RK, Hyer W, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen JT, Clark SK, Hodgson SV. Peutz-Jeghers syndrome: A systematic review and recommendations for management. Gut. 2010;59(7):975–86.CrossRefPubMedGoogle Scholar
  36. 36.
    van Lier MG, Westerman AM, Wagner A, Looman CW, Wilson JH, de Rooij FW, Lemmens VE, Kuipers EJ, Mathus-Vliegen EM, van Leerdam ME. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut. 2011;60(2):141–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Gondak RO, da Silva-Jorge R, Jorge J, Lopes MA, Vargas PA. Oral pigmented lesions: Clinicopathologic features and review of the literature. Med. Oral Patol. Oral Cir. Bucal. 2012;17(6):e919–24.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Richey JD, Bradish JR, Lacy SR, Warren S. Carney syndrome in a patient previously considered to have Peutz-Jeghers syndrome. J. Am. Acad. Dermatol. 2014;70(2):e44–6.CrossRefPubMedGoogle Scholar
  39. 39.
    Bauer AJ, Stratakis CA. The lentiginoses: Cutaneous markers of systemic disease and a window to new aspects of tumourigenesis. J. Med. Genet. 2005;42(11):801–10.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin. Cancer Res. 2006;12(10):3209–15.CrossRefPubMedGoogle Scholar
  41. 41.
    Stratakis CA. Genetics of Carney complex and related familial lentiginoses, and other multiple tumor syndromes. Front. Biosci. 2000;5:D353–66.Google Scholar
  42. 42.
    Winterfield L, Schultz J, Stratakis CA, Cowen EW. Gynecomastia and mucosal lentigines in an 8-year-old boy. J. Am. Acad. Dermatol. 2005;53(4):660–2.CrossRefPubMedGoogle Scholar
  43. 43.
    Gourgari E, Saloustros E, Stratakis CA. Large-cell calcifying sertoli cell tumors of the testes in pediatrics. Curr. Opin. Pediatr. 2012;24(4):518–22.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Crocker MK, Gourgari E, Lodish M, Stratakis CA. Use of aromatase inhibitors in large cell calcifying sertoli cell tumors: Effects on gynecomastia, growth velocity, and bone age. J. Clin. Endocrinol. Metab. 2014;99(12):E2673–80. doi: 10.1210/jc.2014-2530.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Mester J, Eng C. Cowden syndrome: Recognizing and managing a not-so-rare hereditary cancer syndrome. J. Surg. Oncol. 2015;111:125–30.CrossRefPubMedGoogle Scholar
  46. 46.
    Pilarski R. Cowden syndrome: A critical review of the clinical literature. J. Genet. Couns. 2009;18(1):13–27.CrossRefPubMedGoogle Scholar
  47. 47.
    Farooq A, Walker LJ, Bowling J, Audisio RA. Cowden syndrome. Cancer Treat. Rev. 2010;36(8):577–83.CrossRefPubMedGoogle Scholar
  48. 48.
    Yin Y, Shen WH. PTEN: A new guardian of the genome. Oncogene. 2008;27(41):5443–53.CrossRefPubMedGoogle Scholar
  49. 49.
    Lodish MB, Stratakis CA. Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes. Best Pract. Res. Clin. Endocrinol. Metab. 2010;24(3):439–49.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis 1. Am. J. Epidemiol. 2000;151(1):33–40.CrossRefPubMedGoogle Scholar
  51. 51.
    Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch. Neurol. 1988;45(5):575–8.CrossRefGoogle Scholar
  52. 52.
    Zoller ME, Rembeck B, Oden A, Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer. 1997;79(11):2125–31.CrossRefPubMedGoogle Scholar
  53. 53.
    Mao C, Shah A, Hanson DJ, Howard JM. Von Recklinghausen's disease associated with duodenal somatostatinoma: Contrast of duodenal versus pancreatic somatostatinomas. J. Surg. Oncol. 1995;59(1):67–73.CrossRefPubMedGoogle Scholar
  54. 54.
    Hersh JH. Health supervision for children with neurofibromatosis. Pediatrics. 2008;121(3):633–42.CrossRefPubMedGoogle Scholar
  55. 55.
    Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann. N. Y. Acad. Sci. 1991;615:125–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Rosser T, Panigrahy A, McClintock W. The diverse clinical manifestations of tuberous sclerosis complex: A review. Semin. Pediatr. Neurol. 2006;13(1):27–36.CrossRefPubMedGoogle Scholar
  57. 57.
    Dworakowska D, Grossman AB. Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocr Relat Cancer. 2009;16(1):45–58.CrossRefPubMedGoogle Scholar
  58. 58.
    Nandagopal R, Vortmeyer A, Oldfield EH, Keil MF, Stratakis CA. Cushing's syndrome due to a pituitary corticotropinoma in a child with tuberous sclerosis: An association or a coincidence? Clin. Endocrinol. 2007;67(4):639–41.Google Scholar
  59. 59.
    Roach ES, Sparagana SP. Diagnosis of tuberous sclerosis complex. J. Child Neurol. 2004;19(9):643–9.PubMedGoogle Scholar
  60. 60.
    Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 2008;358(2):140–51.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2016

Authors and Affiliations

  1. 1.Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthBethesdaUSA

Personalised recommendations